H&F Corporate Investors VIII Ltd. Buys Shares of 5,387,858 Claritev $CTEV

H&F Corporate Investors VIII Ltd. purchased a new position in shares of Claritev (NYSE:CTEV) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 5,387,858 shares of the company’s stock, valued at approximately $285,988,000. Claritev comprises approximately 100.0% of H&F Corporate Investors VIII Ltd.’s holdings, making the stock its biggest holding. H&F Corporate Investors VIII Ltd. owned about 32.69% of Claritev as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. AustralianSuper Pty Ltd bought a new position in Claritev during the third quarter worth $169,605,000. Vanguard Group Inc. bought a new stake in Claritev in the 3rd quarter valued at $27,483,000. Citigroup Inc. bought a new stake in Claritev in the 3rd quarter valued at $2,025,000. JPMorgan Chase & Co. acquired a new stake in Claritev in the 3rd quarter worth $1,245,000. Finally, Rhumbline Advisers acquired a new stake in Claritev in the 3rd quarter worth $567,000. Institutional investors and hedge funds own 87.15% of the company’s stock.

Insider Buying and Selling at Claritev

In other news, EVP Michael Kim bought 30,000 shares of the company’s stock in a transaction that occurred on Friday, February 27th. The stock was acquired at an average price of $14.30 per share, for a total transaction of $429,000.00. Following the transaction, the executive vice president directly owned 137,973 shares of the company’s stock, valued at $1,973,013.90. This trade represents a 27.78% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Travis Dalton acquired 15,380 shares of the firm’s stock in a transaction on Friday, February 27th. The shares were purchased at an average cost of $13.00 per share, for a total transaction of $199,940.00. Following the completion of the purchase, the chief executive officer directly owned 24,952 shares of the company’s stock, valued at approximately $324,376. The trade was a 160.68% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 8.00% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Wells Fargo & Company set a $30.00 target price on Claritev and gave the stock an “equal weight” rating in a research report on Tuesday, February 24th. Citigroup decreased their price objective on Claritev from $63.00 to $21.00 and set a “buy” rating on the stock in a report on Wednesday, February 25th. Guggenheim restated a “buy” rating on shares of Claritev in a research note on Tuesday, February 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Claritev in a research report on Monday, December 29th. Finally, UBS Group reissued a “buy” rating on shares of Claritev in a report on Tuesday, February 24th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Claritev currently has an average rating of “Hold” and a consensus target price of $29.67.

Claritev Price Performance

Shares of NYSE:CTEV opened at $17.27 on Friday. The business’s fifty day moving average price is $26.39 and its two-hundred day moving average price is $45.17. Claritev has a fifty-two week low of $12.04 and a fifty-two week high of $74.07. The stock has a market capitalization of $285.13 million, a price-to-earnings ratio of -1.00 and a beta of 0.60.

Claritev Company Profile

Claritev is a healthcare technology, data and insights company focused on improving affordability,  transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.